Replimune Group, Inc. (REPL), a clinical-stage biotechnology company, on Wednesday announced the first patient has been dosed in two clinical trials evaluating RP2, its oncolytic immunotherapy.
The RP2-202 trial is a Phase 2/3 study assessing RP2 in combination with nivolumab versus nivolumab and ipilimumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
Approximately 280 patients will be enrolled to evaluate overall survival and progression-free survival as the primary endpoints.
The RP2-003 trial is an open-label study evaluating RP2 combined with atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The study will enroll 30 patients and will focus on overall response rate and duration of response.
RP2 is a novel oncolytic immunotherapy derived from herpes simplex virus and engineered to target and kill tumors while stimulating systemic immune responses.
"We are excited to begin these trials evaluating RP2's potential in treating metastatic uveal melanoma and advanced HCC," said Sushil Patel, Ph.D., CEO of Replimune. "These trials represent important milestones in the development of our RPx platform."
These clinical trials highlight Replimune's continued focus to advancing RP2 and its RPx platform, which aims to deliver targeted and immune-enhancing treatments for cancer patients with limited treatment options.
The company is also progressing with other clinical trials, including the BLA submission for RP1 and ongoing studies for additional indications.
Currently, REPL is trading at $11.43 up by 2.06%
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.